The Pforzheim Tricuspid Valve Registry study is designed to confirm the safety and performance of the TriClip™ device in a contemporary real-world setting in critically ill patients. The observational trial is a prospective, single arm, open-label, single-center, post market registry.
Subjects (>=18 years age) have severe tricuspid regurgitation and are symptomatic despite medical therapy.
Subjects eligible to receive the TriClip™
Subjects must provide written informed consent prior to study procedure.
Subjects participating in another clinical study that may impact the follow-up or results of this study.
Helios Klinikum Pforzheim
Lead sponsor